Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HUEXC030 for Prevention of Anti-TB Drug-Induced Liver Injury
NCT02467608Phase 3Completed
- Sponsor
- Orient Pharma Co., Ltd.
- Start
- Dec 2012
- Primary completion
- Jan 2019
- Countries
- 1
01
Overview
A Phase 3 trial of isoniazid + HUEXC030 in drug induced liver injury (DILI), sponsored by Orient Pharma Co., Ltd.. Started Dec 2012; status: completed.
02
Drugs
isoniazid + HUEXC030
03
Conditions
drug induced liver injury (DILI)
Beyond the preview
Go deeper on NCT02467608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02467608.